237 related articles for article (PubMed ID: 36307214)
41. Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Selleri L; von Lindern M; Hermans A; Meijer D; Torelli G; Grosveld G
Blood; 1990 Mar; 75(5):1146-53. PubMed ID: 2407300
[TBL] [Abstract][Full Text] [Related]
42. Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Bock O; Reising D; Kreipe H
Diagn Mol Pathol; 2003 Sep; 12(3):119-23. PubMed ID: 12960692
[TBL] [Abstract][Full Text] [Related]
43. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
44. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
Rafiei A; Mian AA; Döring C; Metodieva A; Oancea C; Thalheimer FB; Hansmann ML; Ottmann OG; Ruthardt M
PLoS Genet; 2015 Apr; 11(4):e1005144. PubMed ID: 25919613
[TBL] [Abstract][Full Text] [Related]
45. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
46. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
47. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
[TBL] [Abstract][Full Text] [Related]
48. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
49. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Deininger MW; Shah NP; Altman JK; Berman E; Bhatia R; Bhatnagar B; DeAngelo DJ; Gotlib J; Hobbs G; Maness L; Mead M; Metheny L; Mohan S; Moore JO; Naqvi K; Oehler V; Pallera AM; Patnaik M; Pratz K; Pusic I; Rose MG; Smith BD; Snyder DS; Sweet KL; Talpaz M; Thompson J; Yang DT; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2020 Oct; 18(10):1385-1415. PubMed ID: 33022644
[TBL] [Abstract][Full Text] [Related]
50. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
Fujie H; Tsuchiya S; Morita S; Itano M; Yambe T; Ohasi Y; Minegishi N; Minegishi M; Satou T; Konno T
Leukemia; 1994 Sep; 8(9):1592-5. PubMed ID: 8090037
[TBL] [Abstract][Full Text] [Related]
51. [Ph1-positive leukemia: cytogenetic outline and prognosis].
Misawa S
Nihon Rinsho; 1992 Jun; 50(6):1274-80. PubMed ID: 1518145
[TBL] [Abstract][Full Text] [Related]
52. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
Rumpold H; Webersinke G
Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
[TBL] [Abstract][Full Text] [Related]
53. [Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile].
Artigas CG; Melo A; Roa JC; Páez E; Vittini C; Arriagada M; González L; Pflaumer E; Roa I
Rev Med Chil; 2002 Jun; 130(6):623-30. PubMed ID: 12194684
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
55. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612).
Slovak ML; Kopecky KJ; Wolman SR; Henslee-Downey JP; Appelbaum FR; Forman SJ; Blume KG
Leuk Res; 1995 Jun; 19(6):381-8. PubMed ID: 7596150
[TBL] [Abstract][Full Text] [Related]
56. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
57. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Giles FJ; Cortes J; Jones D; Bergstrom D; Kantarjian H; Freedman SJ
Blood; 2007 Jan; 109(2):500-2. PubMed ID: 16990603
[TBL] [Abstract][Full Text] [Related]
58. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.
Adnan-Awad S; Kim D; Hohtari H; Javarappa KK; Brandstoetter T; Mayer I; Potdar S; Heckman CA; Kytölä S; Porkka K; Doma E; Sexl V; Kankainen M; Mustjoki S
Leukemia; 2021 Jul; 35(7):1964-1975. PubMed ID: 33168949
[TBL] [Abstract][Full Text] [Related]
59. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
60. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
